Bremazocine

This classification denotes an opioid receptor agonist with the molecular formula C20H29NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier ISF76M2DBE, chemically known as 2,6-methano-3-benzazocin-8-ol, 6-ethyl-1,2,3,4,5,6-hexahydro-3-((1-hydroxycyclopropyl)methyl)-11,11-dimethyl- but generally known as bremazocine, which bears US NIH Compound Identifier 1223. European Medicines Agency schedules Bremazocine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05884MIG. The term BREMAZOCINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 34, No. 10 1980, List 20). BREMAZOCINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule bremazocine under HS 29333999 and SITC 51574. As of Q4 2014, BREMAZOCINE remains the US FDA Preferred Term for this commodity. Bremazocine bears US NLM identifiers UMLS ID C0054038 and NCI Concept Code C91041. SMILES: OC1(CN2C3C(C(CC2)(C2C(C3)CCC(O)C2)CC)(C)C)CC1.